Hong Kong stocks rose on Tuesday, with the biotech and pharmaceutical outsourcing sectors leading the gains. WUXI APPTEC, a leading contract research and manufacturing services provider, saw its shares surge by a remarkable 6.42%.
The surge in WUXI APPTEC's stock price came amid broader optimism in the Hong Kong market, which saw the Hang Seng Index rise by 1.00% and the Hang Seng Tech Index edge up by 0.27%. WUXI APPTEC's affiliate, WUXI Biologics, also witnessed a significant increase of 7.87%.
Investors are keenly anticipating the upcoming annual Central Economic Work Conference in China, where top leaders are expected to map out economic targets and stimulus plans for 2025. There is optimism that the conference may result in supportive measures for sectors like biotech and pharmaceuticals, where WUXI APPTEC operates.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。